

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 99/02340

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68 C07K14/705 A61K38/10 G06F17/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q A61K C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 92 16547 A (CHILDRENS MEDICAL CENTER) 1 October 1992 (1992-10-01) page 3, line 10 -page 7, line 27; claims 1-3,14-23 ---	1,2,7,8, 10,13-18
A	FAN J ET AL: "Genetic mapping: Finding and analyzing single-nucleotide polymorphisms with high-density DNA arrays" AMERICAN JOURNAL OF HUMAN GENETICS, vol. 61, no. 4, SUPPL, 1 October 1997 (1997-10-01), page 1601 XP002089397 ISSN: 0002-9297 the whole document --- -/--	1-6



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

3 November 1999

Date of mailing of the international search report

17/11/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Osborne, H

INTERNATIONAL SEARCH REPORT

National Application No

PCT/GB 99/02340

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>KRUGLYAK L: "PASSAGE TEXT. THE USE OF A GENETIC MAP OF BIALLELIC MARKERS IN LINKAGE STUDIES" NATURE GENETICS, vol. 17, no. 1, 1 September 1997 (1997-09-01), pages 22-24, XP002050647 ISSN: 1061-4036 the whole document</p> <p style="text-align: center;">---</p>	1-6
A	<p>SACHAIS B: "The neurokinin-1 receptor: mutational and computational analysis of structure function relationships for ligand binding and receptor activation (substance p, tachykinins)i" DISS. ABSTR. INT., vol. 57, no. 6, 1996, page 3594 XP002121352 whole abstract the whole document</p> <p style="text-align: center;">---</p>	1,13-15
A	<p>ROSENKILDE M ET AL: "Mutations along transmembrane segment II of the NK-1 receptor affect substance competition with non-peptide antagonists but not substance P binding" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 45, November 1994 (1994-11), pages 28160-164, XP002121353 the whole document</p> <p style="text-align: center;">---</p>	1,13-15
A	<p>FONG T ET AL: "Mutation analysis of neurokinin receptor function" CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, vol. 73, no. 7, July 1995 (1995-07), pages 860-5, XP002121354 the whole document</p> <p style="text-align: center;">---</p>	1,13-15
A	<p>BRODBECK R ET AL: "Residue 78 in the second transmembrane domain of the neurokinin 1 receptor is important in coupling high affinity agonist binding to multiple second messenger responses" MOLECULAR PHARMACOLOGY, vol. 47, no. 5, May 1995 (1995-05), pages 1065-71, XP002121355 the whole document</p> <p style="text-align: center;">---</p>	1,13-15

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/02340

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	HOPKINS B ET AL: "Isolation and characterisation of the human NK-1 receptor cDNA" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 180, no. 2, October 1991 (1991-10), pages 1110-1117, XP002121356 the whole document	1
A	EP 0 510 878 A (MERCK & CO INC) 28 October 1992 (1992-10-28) page 4, line 23 - line 41; claims 1-3	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

Pct/GB 99/02340

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9216547	A	01-10-1992	NONE	
EP 0510878	A	28-10-1992	CA 2066491 A	26-10-1992
			DE 69227940 D	04-02-1999
			DE 69227940 T	05-08-1999
			JP 2051389 C	10-05-1996
			JP 5208997 A	20-08-1993
			JP 7080910 B	30-08-1995
			US 5484886 A	16-01-1996
			US 5525712 A	11-06-1996

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 99/ 02340

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 13 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)


This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims: it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

PATENT COOPERATION TREATY



PCT

From the INTERNATIONAL BUREAU

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

To:

BILL, Kevin
AstraZeneca
Global Intellectual Property
P.O. Box 272
Mereseide, Alderley Park
Macclesfield, Cheshire SK10 4GR
ROYAUME-UNI

Date of mailing (day/month/year) 26 September 2000 (26.09.00)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference PHM 70365/WO	
International application No. PCT/GB99/02340 0x	International filing date (day/month/year) 20 July 1999 (20.07.99)

1. The following indications appeared on record concerning:

☒ the applicant ☐ the inventor ☐ the agent ☐ the common representative

Name and Address ASTRAZENECA UK LIMITED 15 Stanhope Gate London W1Y 6LN United Kingdom	State of Nationality GB	State of Residence GB
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☒ the person ☐ the name ☐ the address ☐ the nationality ☐ the residence


Name and Address ASTRAZENECA AB S-151 85 Södertälje Sweden	State of Nationality SE	State of Residence SE
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

☒ the receiving Office ☐ the designated Offices concerned
☐ the International Searching Authority ☒ the elected Offices concerned
☒ the International Preliminary Examining Authority ☐ other:

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Aino Metcalfe Telephone No.: (41-22) 338.83.38
---	---



PATENT COOPERATION TREATY

16 MAY 2000 PCT/GB99/02340

COPY
DEC

From the INTERNATIONAL BUREAU

To:

BILL, Kevin
Global Intellectual Property
Mereside, Alderley Park
Macclesfield
Cheshire SK10 4TG
ROYAUME-UNI

NOTIFICATION OF THE RECORDING
OF A CHANGE

(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

Date of mailing (day/month/year) 03 May 2000 (03.05.00)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference PHM 70365/WO	
International application No. PCT/GB99/02340	International filing date (day/month/year) 20 July 1999 (20.07.99)

1. The following indications appeared on record concerning:

☒ the applicant ☐ the inventor ☐ the agent ☐ the common representative

Name and Address

ZENECA LIMITED
15 Stanhope Gate
London W1Y 6LN
United Kingdom

State of Nationality

GB

State of Residence

GB

Telephone No.

Facsimile No.

Teleprinter No.

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☒ the person ☐ the name ☐ the address ☐ the nationality ☐ the residence

Name and Address

ASTRAZENECA UK LIMITED
15 Stanhope Gate
London W1Y 6LN
United Kingdom

State of Nationality

GB

State of Residence

GB

Telephone No.

Facsimile No.

Teleprinter No.

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

☒ the receiving Office ☐ the designated Offices concerned
☐ the International Searching Authority ☒ the elected Offices concerned
☒ the International Preliminary Examining Authority ☐ other:

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Anman CIU

Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

PCT

From the INTERNATIONAL BUREAU

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

To:

BILL, Kevin
AstraZeneca
Global Intellectual Property
P.O. Box 272
Mereside, Alderley Park
Macclesfield, Cheshire SK10 4GR
ROYAUME-UNI

Date of mailing (day/month/year) 26 September 2000 (26.09.00)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference PHM 70365/WO	
International application No. PCT/GB99/02340	International filing date (day/month/year) 20 July 1999 (20.07.99)

1. The following indications appeared on record concerning:

☒ the applicant ☐ the inventor ☐ the agent ☐ the common representative

Name and Address ASTRAZENECA UK LIMITED 15 Stanhope Gate London W1Y 6LN United Kingdom	State of Nationality GB	State of Residence GB
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☒ the person ☐ the name ☐ the address ☐ the nationality ☐ the residence

Name and Address ASTRAZENECA AB S-151 85 Södertälje Sweden	State of Nationality SE	State of Residence SE
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

☒ the receiving Office ☐ the designated Offices concerned
☐ the International Searching Authority ☒ the elected Offices concerned
☒ the International Preliminary Examining Authority ☐ other:

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Aino Metcalfe Telephone No.: (41-22) 338.83.38
--	--

Copy for the Elected Office (EO/US)
PATENT COOPERATION TREATY

PCT/GB99/02340

PCT

**NOTIFICATION OF THE RECORDING
OF A CHANGE**

(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

BILL, Kevin
AstraZeneca
Global Intellectual Property
P.O. Box 272
Mereseide, Alderley Park
Macclesfield, Cheshire SK10 4GR
ROYAUME-UNI

Date of mailing (day/month/year) 26 September 2000 (26.09.00)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference PHM 70365/WO	
International application No. PCT/GB99/02340	International filing date (day/month/year) 20 July 1999 (20.07.99)

1. The following indications appeared on record concerning:

☐ the applicant ☐ the inventor ☒ the agent ☐ the common representative

Name and Address

BILL, Kevin
Global Intellectual Property
Mereseide, Alderley Park
Macclesfield
Cheshire SK10 4TG
United Kingdom

State of Nationality

State of Residence

Telephone No.

01625/512461

Facsimile No.

01625/583358

Teleprinter No.

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☐ the person ☐ the name ☒ the address ☐ the nationality ☐ the residence

Name and Address

BILL, Kevin
AstraZeneca
Global Intellectual Property
P.O. Box 272
Mereseide, Alderley Park
Macclesfield, Cheshire SK10 4GR
United Kingdom

State of Nationality

State of Residence

Telephone No.

01625 514304

Facsimile No.

01625 583358

Teleprinter No.

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

<input checked="" type="checkbox"/> the receiving Office	<input type="checkbox"/> the designated Offices concerned
<input type="checkbox"/> the International Searching Authority	<input checked="" type="checkbox"/> the elected Offices concerned
<input checked="" type="checkbox"/> the International Preliminary Examining Authority	<input type="checkbox"/> other:

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Aino Metcalfe

Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C. 20231
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year)

24 February 2000 (24.02.00)

International application No.

PCT/GB99/02340

Applicant's or agent's file reference

PHM 70365/WO

International filing date (day/month/year)

20 July 1999 (20.07.99)

Priority date (day/month/year)

25 July 1998 (25.07.98)

Applicant

SMITH, John, Craig et al

1. The designated Office is hereby notified of its election made:



in the demand filed with the International Preliminary Examining Authority on:

27 January 2000 (27.01.00)



in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Olivia RANAIVOJAONA

Telephone No.: (41-22) 338.83.38

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference PHM 70365/WO	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/GB 99/ 02340	International filing date (day/month/year) 20/07/1999	(Earliest) Priority Date (day/month/year) 25/07/1998
Applicant ZENECA LIMITED et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets.



It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.



the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing:



contained in the international application in written form.



filed together with the international application in computer readable form.



furnished subsequently to this Authority in written form.



furnished subsequently to this Authority in computer readable form.



the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.



the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,



the text is approved as submitted by the applicant.



the text has been established by this Authority to read as follows:

GENETIC POLYMORPHISMS IN THE HUMAN NEUROKININ 1 RECEPTOR GENE AND THEIR USES IN DIAGNOSIS AND TREATMENT OF DISEASES

5. With regard to the **abstract**,



the text is approved as submitted by the applicant.



the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.



as suggested by the applicant.



because the applicant failed to suggest a figure.



because this figure better characterizes the invention.



None of the figures.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 99/02340

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 13 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference LDSG/PHM70365/WO	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416) FOR FURTHER ACTION	
International application No. PCT/GB99/02340	International filing date (day/month/year) 20/07/1999	Priority date (day/month/year) 25/07/1998
International Patent Classification (IPC) or national classification and IPC C12Q1/68		
Applicant ASTRAZENECA UK LIMITED et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 7 sheets, including this cover sheet.

☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☒ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 27/01/2000	Date of completion of this report 06.10.2000
Name and mailing address of the international preliminary examining authority: <div style="display: flex; align-items: center;"> <div> European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465 </div> </div>	Authorized officer Knudsen, H Telephone No. +49 89 2399 8696



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB99/02340

I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

Description, pages:

1-26 as originally filed

Claims, No.:

1-18 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

see separate sheet

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
- ☒ claims Nos. 13 (IA).

because:

- ☒ the said international application, or the said claims Nos. 13 (IA) relate to the following subject matter which does not require an international preliminary examination (*specify*):

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/GB99/02340

see separate sheet

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- ☐ no international search report has been established for the said claims Nos. .

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1-14,16-18
	No:	Claims	15
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-18
Industrial applicability (IA)	Yes:	Claims	1-12,14-18
	No:	Claims	

2. Citations and explanations

see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

see separate sheet


VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY



To:

Bill, Kevin
GLOBAL INTELLECTUAL PROPERTY
ASTRAZENECA UK LIMITED
Mereside, Alderley Park
Macclesfield
Cheshire SK10 4TG
GRANDE BRETAGNE

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL PRELIMINARY
EXAMINATION REPORT
(PCT Rule 71.1)

Date of mailing
(day/month/year) 06.10.2000

Applicant's or agent's file reference
LDSG/PHM70365/WO

IMPORTANT NOTIFICATION

International application No.
PCT/GB99/02340

International filing date (day/month/year)
20/07/1999

Priority date (day/month/year)
25/07/1998

Applicant
ASTRAZENECA UK LIMITED et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.
4. **REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/



European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized officer

Danti, B

Tel. +49 89 2399-8161



ITEM I:

The original application documents also contain sequence listing pages 1-3.

ITEM III:

- 3.1 Claim 13 relates to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

ITEM V:

NOVELTY:

- 5.1 None of the cited prior art documents disclose a diagnostic method in which the sequence of the NK-1R (neuromedin K-1 receptor) gene is determined. The closest prior art is disclosed in WO 93/03137 (D1) and "Biochem. Biophys. Res. Comm., vol.179, p.1232-1240, (1991)" (D2) both of which are not cited in the International Search Report. Both D1 and D2 disclose a cDNA sequence encoding human substance P receptor. "Substance P receptor" appears to be another name for the NK1R. However, the sequence is not determined as part of a method for diagnosis. Claims 1-6 and 13-14 are therefore novel.
- 5.2 The sequence disclosed in D1 and D2 is identical to the SEQ ID NO.1 in a 604 bp overlap, apart from the C \Rightarrow T mutation at position 2361. Also the other mutations are not mentioned in the cited prior art documents. Claims 7-11 and 16 is therefore novel over these documents.
- 5.3 Also the deletion mutation mentioned in claim 12 is not mentioned in the cited prior art documents.
- 5.4 NK-1R antagonists are known from the prior art (cf page 6, last paragraph of the present application's description). Thus claim 15, which is defined by the content of NK-1R antagonist and instructions for administration, lacks novelty, instructions for administration do not constitute a technical feature of the invention.

- 5.5 Finally, the cited prior art documents do not disclose a comparison of sequences of the NK-1R gene. Thus, claims 17-18 appear to be novel as well.

INVENTIVE STEP:

- 5.6 The IPEA agrees with the applicant that it is not obvious to the skilled person that the SNP mutations mentioned in claim 1 exist. Thus, the skilled person would not have any reasons to look for these SNPs as part of a method for diagnosis. Nevertheless, it is nowhere in the application disclosed what the technical effect of the identification of any of the SNPs mentioned in claim 1 can be used for. The description only speculates that a pharmaceutical treatment can be adapted according to the SNPs found in a patient. It is therefore not clear whether a technical problem is, in fact, solved by the method of claim 1 and an inventive step therefore cannot be acknowledged for claims 1-2, 6 and 13-14.
- 5.7 The same line of argumentation applies to the nucleic acids containing the said SNPs, the development of primers capable of detecting the said SNPs, computer media containing the said media and methods for sequence identification. Claims 7-11 and 16 therefore do not appear to be inventive.
- 5.8 The method steps mentioned in claims 3-5 are routine techniques used by the skilled person who wishes to identify polymorphisms and therefore does not add anything inventive to the claims to which they refer.
- 5.9 Also for the allelic variant having a C-terminal deletion of 36 base pairs, the application does not disclose any association with a disease or pharmaceutical treatment. Thus, it is not clear whether the allelic variant solves a technical problem and an inventive step therefore cannot be acknowledged for claim 12.

INDUSTRIAL APPLICABILITY:

- 5.10 For the assessment of the present claim 13 on the question whether it is industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of

claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

ITEM VII:

- 7.1 Contrary to the requirements of Rule 5(a)(ii) PCT, the closest prior art document D1 is not identified in the description and the relevant background art disclosed therein is not briefly discussed.

ITEM VIII:

- 8.1 The method of claim 1 contains the steps necessary for determining the sequence of the nucleic acid, but not for carrying out a diagnosis of a disease. The wording "method for diagnosis" in claim 1 therefore appears to be incorrect.
- 8.2 The content of claim 5 is not immediately understandable due to the abbreviation "ARMS".
- 8.3 The description only mentions that asthma may be a disease mediated by NK-1R. However, there is no evidence that any of the polymorphisms identified in claim 1 has an effect on the predisposition or susceptibility of an individual to any disease and the methods of claims 1-6 and 13-14 therefore lack support in the description.
- 8.4 The difference between "a diagnostic nucleic acid primer" in claim 8 and "an allele-specific oligonucleotide probe" in claim 10 is not clear. The same subject-matter therefore appears to be claimed twice and the claims, as a whole, therefore appear to lack conciseness.
- 8.5 The C-terminal deletion mentioned in claim 12 has formal support in the description (page 14, penultimate paragraph). However, no other information is given on this polymorphism and claim 12 therefore lacks substantial support in the description.
- 8.6 The definition of the claimed subject-matter by reference to EMBL access nos. equates a definition by reference to prior art documents. This is not acceptable as

INTERNATIONAL PRELIMINARY

International application No. PCT/GB99/02340

EXAMINATION REPORT - SEPARATE SHEET

the application must be comprehensible when read alone.

PCT

REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

For receiving Office use only

International Application No.

International Filing Date

Name of receiving Office and "PCT International Application"

Applicant's or agent's file reference
(if desired) (12 characters maximum) PHM 70365/WO

Box No. I TITLE OF INVENTION

CHEMICAL COMPOUNDS

Box No. II APPLICANT

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

ZENECA Limited
15 Stanhope Gate
LONDON
W1Y 6LN

☐ This person is also inventor.

Telephone No.

(01625) 512461

Facsimile No.

(01625) 583358

Teleprinter No.

669095/669388 ZENPHA G

State (that is, country) of nationality:
GB

State (that is, country) of residence:
GB

This person is applicant for the purposes of: ☐ all designated States ☒ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

SMITH, John Craig
Alderley Park
Macclesfield
Cheshire
SK10 4TG
GB

This person is:

☐ applicant only

☒ applicant and inventor

☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:
GB

State (that is, country) of residence:
GB

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

☒ Further applicants and/or (further) inventors are indicated on a continuation sheet.

Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE

The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:

☒ agent

☐ common representative

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

BILL, Kevin
Global Intellectual Property
Mereside, Alderley Park
Macclesfield
Cheshire SK10 4TG
GB

Telephone No.

(01625) 512461

Facsimile No.

(01625) 583358

Teleprinter No.

669095/669388 ZENPHA G

☐ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

Continuation of Box No. III FURTHER APPLICANTS AND/OR (FURTHER) INVENTORS

If none of the following sub-boxes is used, this sheet should not be included in the request.

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

ANAND, Rakesh
Alderley Park
Macclesfield
Cheshire
SK10 4TG
GB

This person is:

- ☐ applicant only
☒ applicant and inventor
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:
GB

State (that is, country) of residence:
GB

This person is applicant for the purposes of:

- ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

MORTEN, John Edward Norris
Alderley Park
Macclesfield
Cheshire
SK10 4TG
GB

This person is:

- ☐ applicant only
☒ applicant and inventor
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:
GB

State (that is, country) of residence:
GB

This person is applicant for the purposes of:

- ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- ☐ applicant only
☐ applicant and inventor
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of:

- ☐ all designated States ☐ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- ☐ applicant only
☐ applicant and inventor
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of:

- ☐ all designated States ☐ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

☐ Further applicants and/or (further) inventors are indicated on another continuation sheet.

Box No.V DESIGNATION OF STATES

The following designations are hereby made under Rule 4.9(a) (mark the applicable check-boxes; at least one must be marked):

Regional Patent

- ☒ **AP ARIPO Patent:** GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, SD Sudan, SZ Swaziland, UG Uganda, ZW Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT
- ☒ **EA Eurasian Patent:** AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT
- ☒ **EP European Patent:** AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, CY Cyprus, DE Germany, DK Denmark, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, and any other State which is a Contracting State of the European Patent Convention and of the PCT
- ☒ **OA OAPI Patent:** BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, GW Guinea-Bissau, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (if other kind of protection or treatment desired, specify on dotted line)

National Patent (if other kind of protection or treatment desired, specify on dotted line):

- | | |
|--|--|
| <input checked="" type="checkbox"/> AL Albania | <input checked="" type="checkbox"/> LS Lesotho |
| <input checked="" type="checkbox"/> AM Armenia | <input checked="" type="checkbox"/> LT Lithuania |
| <input checked="" type="checkbox"/> AT Austria | <input checked="" type="checkbox"/> LU Luxembourg |
| <input checked="" type="checkbox"/> AU Australia | <input checked="" type="checkbox"/> LV Latvia |
| <input checked="" type="checkbox"/> AZ Azerbaijan | <input checked="" type="checkbox"/> MD Republic of Moldova |
| <input checked="" type="checkbox"/> BA Bosnia and Herzegovina | <input checked="" type="checkbox"/> MG Madagascar |
| <input checked="" type="checkbox"/> BB Barbados | <input checked="" type="checkbox"/> MK The former Yugoslav Republic of Macedonia |
| <input checked="" type="checkbox"/> BG Bulgaria | <input checked="" type="checkbox"/> MN Mongolia |
| <input checked="" type="checkbox"/> BR Brazil | <input checked="" type="checkbox"/> MW Malawi |
| <input checked="" type="checkbox"/> BY Belarus | <input checked="" type="checkbox"/> MX Mexico |
| <input checked="" type="checkbox"/> CA Canada | <input checked="" type="checkbox"/> NO Norway |
| <input checked="" type="checkbox"/> CH and LI Switzerland and Liechtenstein | <input checked="" type="checkbox"/> NZ New Zealand |
| <input checked="" type="checkbox"/> CN China | <input checked="" type="checkbox"/> PL Poland |
| <input checked="" type="checkbox"/> CU Cuba | <input checked="" type="checkbox"/> PT Portugal |
| <input checked="" type="checkbox"/> CZ Czech Republic | <input checked="" type="checkbox"/> RO Romania |
| <input checked="" type="checkbox"/> DE Germany | <input checked="" type="checkbox"/> RU Russian Federation |
| <input checked="" type="checkbox"/> DK Denmark | <input checked="" type="checkbox"/> SD Sudan |
| <input checked="" type="checkbox"/> EE Estonia | <input checked="" type="checkbox"/> SE Sweden |
| <input checked="" type="checkbox"/> ES Spain | <input checked="" type="checkbox"/> SG Singapore |
| <input checked="" type="checkbox"/> FI Finland | <input checked="" type="checkbox"/> SI Slovenia |
| <input checked="" type="checkbox"/> GB United Kingdom | <input checked="" type="checkbox"/> SK Slovakia |
| <input checked="" type="checkbox"/> GD Grenada | <input checked="" type="checkbox"/> SL Sierra Leone |
| <input checked="" type="checkbox"/> GE Georgia | <input checked="" type="checkbox"/> TJ Tajikistan |
| <input checked="" type="checkbox"/> GH Ghana | <input checked="" type="checkbox"/> TM Turkmenistan |
| <input checked="" type="checkbox"/> GM Gambia | <input checked="" type="checkbox"/> TR Turkey |
| <input checked="" type="checkbox"/> HR Croatia | <input checked="" type="checkbox"/> TT Trinidad and Tobago |
| <input checked="" type="checkbox"/> HU Hungary | <input checked="" type="checkbox"/> UA Ukraine |
| <input checked="" type="checkbox"/> ID Indonesia | <input checked="" type="checkbox"/> UG Uganda |
| <input checked="" type="checkbox"/> IL Israel | <input checked="" type="checkbox"/> US United States of America |
| <input checked="" type="checkbox"/> IN India | <input checked="" type="checkbox"/> UZ Uzbekistan |
| <input checked="" type="checkbox"/> IS Iceland | <input checked="" type="checkbox"/> VN Viet Nam |
| <input checked="" type="checkbox"/> JP Japan | <input checked="" type="checkbox"/> YU Yugoslavia |
| <input checked="" type="checkbox"/> KE Kenya | <input checked="" type="checkbox"/> ZW Zimbabwe |
| <input checked="" type="checkbox"/> KG Kyrgyzstan | |
| <input checked="" type="checkbox"/> KP Democratic People's Republic of Korea | |
| <input checked="" type="checkbox"/> KR Republic of Korea | |
| <input checked="" type="checkbox"/> KZ Kazakhstan | |
| <input checked="" type="checkbox"/> LC Saint Lucia | <input checked="" type="checkbox"/> AE United Arab Emirates |
| <input checked="" type="checkbox"/> LK Sri Lanka | <input checked="" type="checkbox"/> ZA South Africa |
| <input checked="" type="checkbox"/> LR Liberia | <input type="checkbox"/> |

Check-boxes reserved for designating States (for the purposes of a national patent) which have become party to the PCT after issuance of this sheet:

Precautionary Designation Statement: In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except any designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation of a designation consists of the filing of a notice specifying that designation and the payment of the designation and confirmation fees. Confirmation must reach the receiving Office within the 15-month time limit.)

Box No. VI PRIORITY CLAIM		<input type="checkbox"/> Further priority claims are indicated in the Supplemental Box.		
Filing date of earlier application (day/month/year)	Number of earlier application	Where earlier application is:		
		national application: country	regional application:* regional Office	international application: receiving Office
item (1) 25/07/98 (25-Jul-98)	9816192.0			
item (2) 22/08/98 (22-Aug-98)	9818280.1			
item (3)				

☒ The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) (only if the earlier application was filed with the Office which for the purposes of the present international application is the receiving Office) identified above as item(s): items 1 & 2

* Where the earlier application is an ARIPO application, it is mandatory to indicate in the Supplemental Box at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed (Rule 4.10(b)(ii)). See Supplemental Box.

Box No. VII INTERNATIONAL SEARCHING AUTHORITY


Choice of International Searching Authority (ISA) (if two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two-letter code may be used):	Request to use results of earlier search; reference to that search (if an earlier search has been carried out by or requested from the International Searching Authority):
ISA /	Date (day/month/year) Number Country (or regional Office)

Box No. VIII CHECK LIST; LANGUAGE OF FILING

This international application contains the following number of sheets: request : 4 description (excluding sequence listing part) : 26 claims : 7 abstract : 1 drawings : sequence listing part of description : 3 Total number of sheets : 41	This international application is accompanied by the item(s) marked below: 1. <input checked="" type="checkbox"/> fee calculation sheet 2. <input checked="" type="checkbox"/> separate signed power of attorney 3. <input type="checkbox"/> copy of general power of attorney; reference number, if any: 4. <input type="checkbox"/> statement explaining lack of signature 5. <input type="checkbox"/> priority document(s) identified in Box No. VI as item(s): 6. <input type="checkbox"/> translation of international application into (language): 7. <input type="checkbox"/> separate indications concerning deposited microorganism or other biological material 8. <input checked="" type="checkbox"/> nucleotide and/or amino acid sequence listing in computer readable form 9. <input type="checkbox"/> other (specify):
Figure of the drawings which should accompany the abstract:	Language of filing of the international application: <u>ENGLISH</u>

Box No. IX SIGNATURE OF APPLICANT OR AGENT

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).


 BILL, Kevin
 Agent for Applicants

For receiving Office use only

1. Date of actual receipt of the purported international application:	2. Drawings: <input type="checkbox"/> received: <input type="checkbox"/> not received:
3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:	
4. Date of timely receipt of the required corrections under PCT Article 11(2):	
5. International Searching Authority (if two or more are competent): <u>ISA /</u>	
6. <input type="checkbox"/> Transmittal of search copy delayed until search fee is paid.	

For International Bureau use only

Date of receipt of the record copy by the International Bureau:

PCT

FEE CALCULATION SHEET

Annex to the Request

For receiving Office use only

International application No.

Date stamp of the receiving Office

Applicant's or agent's
file reference

PHM.70365/WO

Applicant

ZENECA LIMITED

CALCULATION OF PRESCRIBED FEES

1. TRANSMITTAL FEE 55.00 T

2. SEARCH FEE 812.00 S

International search to be carried out by

(If two or more International Searching Authorities are competent in relation to the international application, indicate the name of the Authority which is chosen to carry out the international search.)

3. INTERNATIONAL FEE

Basic Fee

The international application contains 41 sheets.

first 30 sheets 285.00 b1

11 x 6 = 66.00 b2

remaining sheets additional amount

Add amounts entered at b1 and b2 and enter total at B 351.00 B

Designation Fees

The international application contains 79 designations.

10 x 65 = 650.00 D

number of designation fees amount of designation fee payable (maximum 11)

Add amounts entered at B and D and enter total at I 1001.00 I

(Applicants from certain States are entitled to a reduction of 75% of the international fee. Where the applicant is (or all applicants are) so entitled, the total to be entered at I is 25% of the sum of the amounts entered at B and D.)

4. FEE FOR PRIORITY DOCUMENT (if applicable) 44.00 P

5. TOTAL FEES PAYABLE 1912.00

Add amounts entered at T, S, I and P, and enter total in the TOTAL box

TOTAL

☐ The designation fees are not paid at this time.

MODE OF PAYMENT

☐ authorization to charge deposit account (see below)

☒ cheque

☐ postal money order

☐ bank draft

☐ cash

☐ revenue stamps

☐ coupons

☐ other (specify):

DEPOSIT ACCOUNT AUTHORIZATION (this mode of payment may not be available at all receiving Offices)

The RO/ ☐ is hereby authorized to charge the total fees indicated above to my deposit account.

☒ is hereby authorized to charge any deficiency or credit any overpayment in the total fees indicated above to my deposit account.

☒ is hereby authorized to charge the fee for preparation and transmittal of the priority document to the International Bureau of WIPO to my deposit account.

D02934

20th July 1999

Deposit Account No.

Date (day/month/year)

Signature Joanne Margaret Marshall
AUTHORISED OFFICER

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12Q 1/68, C07K 14/705, A61K 38/10, G06F 17/00		A1	(11) International Publication Number: WO 00/06768
		(43) International Publication Date: 10 February 2000 (10.02.00)	
(21) International Application Number: PCT/GB99/02340 (22) International Filing Date: 20 July 1999 (20.07.99) (30) Priority Data: 9816192.0 25 July 1998 (25.07.98) GB 9818280.1 22 August 1998 (22.08.98) GB (71) Applicant (for all designated States except US): ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): SMITH, John, Craig [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). ANAND, Rakesh [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). MORTEN, John, Edward, Norris [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). (74) Agent: BILL, Kevin; Global Intellectual Property, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	
(54) Title: GENETIC POLYMORPHISMS IN THE HUMAN NEUROKININ 1 RECEPTOR GENE AND THEIR USES IN DIAGNOSIS AND TREATMENT OF DISEASES			
(57) Abstract This invention relates to nine single nucleotide polymorphisms in the human NK1R gene (1 in the regulatory region, 2 in coding regions, 2 in flanking intron sequence, 4 in the 3' UTR region) and corresponding novel allelic polypeptides encoded thereby. The invention also relates to methods and materials for analysing allelic variation in the NK1R gene and to the use of said polymorphism in the diagnosis and treatment of NK1R ligand mediated diseases, such as asthma.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

GENETIC POLYMORPHISMS IN THE HUMAN NEUROKININ 1 RECEPTOR GENE AND THEIR USES IN DIAGNOSIS AND TREATMENT OF DISEASES

This invention relates to polymorphisms in the human NK1R gene and corresponding novel allelic polypeptides encoded thereby. The invention also relates to methods and materials for analysing allelic variation in the NK1R gene and to the use of said polymorphism in the diagnosis and treatment of NK1R ligand mediated diseases, such as asthma.

The reader is referred to the following publications for background information: Primary structure and gene organization of human substance P and neuromedin K receptors, K Takahashi *et al* Eur J Biochem **204**, 1025-1033 (1992); Differential activation of intracellular effector by two isoforms of the human neurokinin-1 receptor, TM Fong *et al* Molecular Pharmacology **41**,24-30 (1992); Human Substance P receptor (NK-1): organisation of the gene, chromosome localization, and functional expression of cDNA clones, Gerard *et al* Biochemistry **30**, 10640-10646 (1991); Isolation and characterization of the human lung NK-1 receptor cDNA, Hopkins *et al*, Biochem Biophys Res Commun **180**,110-1117 (1991); Mutational analysis of neurokinin receptor function. TM Fong *et al* Can J Physiol Pharmacol **73**, 860-865 (1995); Structure and function of G protein-coupled receptors, CD Strader *et al* Annual Reviews Biochemistry **63**,101-132 (1994); The evolution and structure of aminergic G protein-coupled receptors, D Donnelly *et al* Receptors and Channels **2**, 61-78 (1994). NK1R polypeptide is known to exist in 2 isoforms, which are possibly alternatively spliced variants of a single NK1R gene, see TM Fong *et al* Molecular Pharmacology **41**,24-30 (1992). A cDNA encoding NK1R has been published in International patent application WO 92/16547, Children's Medical Center; and in European patent application EP 510 878, Merck.

The complete genomic sequence of NK1R is not presently known but regions thereof containing exons 1, 3 & 5 have been published by EMBL as follows: Exon 1, Accession Number X 65177, 2472 bp; Exon 3, Accession Number X65179, 373 bp; Exon 5, Accession Number X65181, 3929 bp. Apart from Accession Number X 65177, all positions herein relate to the positions indicated therein unless stated otherwise or apparent from the context. The inventors have discovered that part of the sequence presented in EMBL Accession Number X65177 is incorrect. Sequencing of genomic PCR products by the present inventors, has shown that the nucleotide sequence from positions 262 - 758 of EMBL Accession Number X65177 is incorrect and a Blast search of the data bases has shown that this

erroneous sequence actually corresponds to positions 1231-1729 of EMBL Accession Number U37688 which encodes a gene similar to the human c-myc proto-oncogene. None of the specific polymorphisms identified herein however, fall within this erroneous sequence.

A sequence containing the promoter region of the human NK1R gene has been published
5 in "Structure, expression and second messenger-mediated regulation of the human and rat substance P receptors and their genes" JE Krause et al Regulatory Peptides 46, 59-66 (1993), (see Figure 2 - Conservation of the human and rat Substance P receptor gene putative promoter regions). The present inventors have confirmed that this sequence is correct. No accession number has been assigned to this published sequence. In view of the sequence error
10 in EMBL X 65177, the corrected sequence is included herein as SEQ ID No. 1. This sequence has been used as the reference sequence for locating the position of the novel promoter and exon 1 (+ intron junction region) polymorphic variants of the NK1R gene identified herein.

With respect to SEQ ID No.1, nucleotides 1 - 261 correspond to sequences 1 - 261 in X
15 65177, sequence 262-833 replaces sequence 262-758 of X 65177 (resulting in an addition of 75 nucleotides to the complete sequence length) and sequence 834 - 2547 corresponds to sequence 759- 2472 of X 65177. Exon 1 ATG starts at position 2029 and ends at position 2417.

One approach is to use knowledge of polymorphisms to help identify patients most suited
20 to therapy with particular pharmaceutical agents (this is often termed "pharmacogenetics"). Pharmacogenetics can also be used in pharmaceutical research to assist the drug selection process. Polymorphisms are used in mapping the human genome and to elucidate the genetic component of diseases. The reader is directed to the following references for background details on pharmacogenetics and other uses of polymorphism detection: Linder *et al.* (1997),
25 Clinical Chemistry, 43, 254; Marshall (1997), Nature Biotechnology, 15, 1249; International Patent Application WO 97/40462, Spectra Biomedical; and Schafer *et al.* (1998), Nature Biotechnology, 16, 33.

A haplotype is a set of alleles found at linked polymorphic sites (such as within a gene) on a single (paternal or maternal) chromosome. If recombination within the gene is random,
30 there may be as many as 2^n haplotypes, where 2 is the number of alleles at each SNP and n is the number of SNPs. One approach to identifying mutations or polymorphisms which are correlated with clinical response is to carry out an association study using all the haplotypes

that can be identified in the population of interest. The frequency of each haplotype is limited by the frequency of its rarest allele, so that SNPs with low frequency alleles are particularly useful as markers of low frequency haplotypes. As particular mutations or polymorphisms associated with certain clinical features, such as adverse or abnormal events, are likely to be
5 of low frequency within the population, low frequency SNPs may be particularly useful in identifying these mutations (for examples see: Linkage disequilibrium at the cystathionine beta synthase (CBS) locus and the association between genetic variation at the CBS locus and plasma levels of homocysteine. *Ann Hum Genet* (1998) 62:481-90, De Stefano V, Dekou V, Nicaud V, Chasse JF, London J, Stansbie D, Humphries SE, and Gudnason V; and Variation
10 at the von willebrand factor (vWF) gene locus is associated with plasma vWF:Ag levels: identification of three novel single nucleotide polymorphisms in the vWF gene promoter. *Blood* (1999) 93:4277-83, Keightley AM, Lam YM, Brady JN, Cameron CL, Lillicrap D).

Clinical trials have shown that patient response to treatment with pharmaceuticals is often heterogeneous. Thus there is a need for improved approaches to pharmaceutical agent design
15 and therapy.

Point mutations in polypeptides will be referred to as follows: natural amino acid (using 1 or 3 letter nomenclature) , position, new amino acid. For (a hypothetical) example, "D25K" or "Asp25Lys" means that at position 25 an aspartic acid (D) has been changed to lysine (K). Multiple mutations in one polypeptide will be shown between square brackets with individual
20 mutations separated by commas.

The present invention is based on the discovery of single nucleotide polymorphisms (SNPs) in the NK1R gene. As defined herein, the NK1R gene includes exon coding sequence, intron sequences intervening the exon sequences and, 3' and 5' untranslated region (3' UTR and 5' UTR) sequences, including the promoter element of the NK1R gene.

25 According to one aspect of the present invention there is provided a method for the diagnosis of a single nucleotide polymorphism in NK1R in a human, which method comprises determining the sequence of the nucleic acid of the human at one or more of positions:
2286 in exon 1 as defined by the position in EMBL ACCESSION NO. X 65177;
271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;
30 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;
245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181;
and determining the status of the human by reference to polymorphism in the NK1R gene.

According to another aspect of the present invention there is provided a method for diagnosis of a single nucleotide polymorphism in NK1R in a human, which method comprises determining the sequence of the nucleic acid of the human at one or more positions:

- 2286 in exon 1 as defined by the position in EMBL ACCESSION NO. X 65177;
 - 5 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;
 - 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;
 - 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181;
 - 461 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
 - 495 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
 - 10 600 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
 - 809 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
- and determining the status of the human by reference to polymorphism in NK1R or its 3' untranslated region.

According to another aspect of the present invention there is provided a method for
15 diagnosis of one or more single nucleotide polymorphism(s) in NK1R gene in a human, which method comprises determining the sequence of the nucleic acid of the human at one or more positions:

- 2361 in exon 1 as defined by the position in SEQ ID No. 1;
 - 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;
 - 20 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;
 - 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181;
 - 461 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
 - 495 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
 - 600 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
 - 25 809 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
 - 1371 in the promoter element as defined by the position in SEQ ID No. 1;
- and determining the status of the human by reference to polymorphism in NK1R.

The term human includes both a human having or suspected of having a NK1R ligand mediated disease and an asymptomatic human who may be tested for predisposition or
30 susceptibility to such disease. At each position the human may be homozygous for an allele or the human may be a heterozygote.

In one embodiment of the invention preferably the method for diagnosis described herein is one in which the single nucleotide polymorphism at position 2361 in exon 1 is presence of C and/or T.

In another embodiment of the invention preferably the method for diagnosis described
5 herein is one in which the single nucleotide polymorphism at position 271 near exon 3 is presence of G and/or T.

In another embodiment of the invention preferably the method for diagnosis described herein is one in which the single nucleotide polymorphism at position 272 near exon 3 is presence of A and/or a single base deletion at this position.

10 In another embodiment of the invention preferably the method for diagnosis described herein is one in which the single nucleotide polymorphism at position 245 in exon 5 is presence of C and/or a single base deletion at this position. This results in premature termination and loss of C-terminal 26 amino acids (see Example 1 below). Testing for the presence of this polymorphism is especially preferred because, without wishing to be bound
15 by theoretical considerations, of its association with a significant loss of amino acids.

In another embodiment of the invention preferably the method for diagnosis described herein is one in which the single nucleotide polymorphism at position 461 in the 3'UTR is presence of G and/or C.

In another embodiment of the invention preferably the method for diagnosis described
20 herein is one in which the single nucleotide polymorphism at position 495 in the 3'UTR is the presence of T and/or a single base insertion of A at this position.

In another embodiment of the invention preferably the method for diagnosis described herein is one in which the single nucleotide polymorphism at position 600 in the 3'UTR is presence of A and/or G.

25 In another embodiment of the invention preferably the method for diagnosis described herein is one in which the single nucleotide polymorphism at position 809 in the 3'UTR is presence of C and/or T.

In another embodiment of the invention preferably the method for diagnosis described herein is one in which the single nucleotide polymorphism at position 1371 in the promoter
30 element is presence of A and/or G.

When considering positional relationships in the presence of a single base deletion or insertion the introduction of an appropriate gap is required in accordance with established techniques.

In another aspect of the invention we provide a method for the diagnosis of NK1R
5 ligand-mediated disease, which method comprises:
i) obtaining sample nucleic acid from an individual,
detecting the presence or absence of a variant nucleotide at one or more of positions:
2361 in exon 1 as defined by the position in SEQ ID No. 1;
271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;
10 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;
245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181;
461 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
495 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
600 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
15 809 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
1371 in the promoter element as defined by the position in SEQ ID No. 1;
and determining the status of the human by reference to polymorphism in NK1R.

The method for diagnosis is preferably one in which the sequence is determined by a
method selected from allele specific amplification (i.e. ARMS™-allele specific amplification;
20 ARMS referring to amplification refractory mutation system), allele specific hybridisation
(ASH), oligonucleotide ligation assay (OLA) and restriction fragment length polymorphism
(RFLP).

The status of the human may be determined by reference to allelic variation at any one,
two, three, four, five, six, seven, eight or all nine positions. The status of the human may also
25 be determined by one or more of the specific polymorphisms identified herein in combination
with one or more other SNP's.

NK1 antagonists have been explored by Glaxo, Pfizer, Merck, Parke-Davis, Lilly, RPR,
and Sanofi, primarily for CNS indications. In a recent clinical trial it was reported that a
single dose of Pfizer CP-122,721 inhibits emesis associated with chemotherapy and was well
30 tolerated with no adverse effects (Kris *et al*, JNCI, 89, 817, 1997). Most recently Merck has
announced positive Phase II studies with a NK1 antagonist in depression/anxiety.

It is believed that a dual NK1/ NK2 receptor antagonist will have some clinical utility, particularly for asthma. As compared with conventional therapies, it is expected that a dual NK1/NK2 receptor antagonist will better control airways hyper-responsiveness and neurogenic inflammation (extravasation and hypersecretion), both of which are characteristic manifestations of asthma. This multifaceted approach improves upon other therapies that are designed to treat only a single clinical manifestation of this disease. Other therapeutic opportunities for NK1/NK2 antagonist exist in pain, migraine, anxiety, depression, urinary incontinence, and inflammatory bowel disease.

Four companies have published on mixed NK1/NK2 receptor antagonists. Two of the compounds are peptides: FK-224 (Fujisawa) and S16474 (Servier). The other two, MDL-105,212 (Marion Merrell Dow) and a recent compound from Merck, are structurally related to the selective NK2 antagonist, SR48968 (Sanofi). Neurokinin receptor antagonists have been reviewed by C J Swain (1996) in *Exp. Opin. Ther. Patents*, 6, 367-378; and by Elliot & Seward (1997) in *Exp. Opin. Ther. Patents*, 7, 43-54.

The test sample of nucleic acid is conveniently a sample of blood, bronchoalveolar lavage fluid, sputum, urine or other body fluid or tissue obtained from an individual. It will be appreciated that the test sample may equally be a nucleic acid sequence corresponding to the sequence in the test sample, that is to say that all or a part of the region in the sample nucleic acid may firstly be amplified using any convenient technique e.g. PCR, before analysis of allelic variation.

It will be apparent to the person skilled in the art that there are a large number of analytical procedures which may be used to detect the presence or absence of variant nucleotides at one or more polymorphic positions of the invention. In general, the detection of allelic variation requires a mutation discrimination technique, optionally an amplification reaction and optionally a signal generation system. Table 1 lists a number of mutation detection techniques, some based on the polymerase chain reaction (PCR). These may be used in combination with a number of signal generation systems, a selection of which is listed in Table 2. Further amplification techniques are listed in Table 3. Many current methods for the detection of allelic variation are reviewed by Nollau *et al.*, *Clin. Chem.* 43, 1114-1120, 1997; and in standard textbooks, for example "Laboratory Protocols for Mutation Detection", Ed. by U. Landegren, Oxford University Press, 1996 and "PCR", 2nd Edition by Newton & Graham, BIOS Scientific Publishers Limited, 1997.

Abbreviations:

ALEX™	Amplification refractory mutation system linear extension
APEX	Arrayed primer extension
ARMS™	Amplification refractory mutation system
b-DNA	Branched DNA
CMC	Chemical mismatch cleavage
bp	base pair
COPS	Competitive oligonucleotide priming system
DGGE	Denaturing gradient gel electrophoresis
FRET	Fluorescence resonance energy transfer
LCR	Ligase chain reaction
MASDA	Multiple allele specific diagnostic assay
MCP-1	Monocyte chemoattractant protein 1
NASBA	Nucleic acid sequence based amplification
NK	Neurokinin
NK1R	Neurokinin 1 receptor
NK2R	Neurokinin 2 receptor
OLA	Oligonucleotide ligation assay
PCR	Polymerase chain reaction
PTT	Protein truncation test
RFLP	Restriction fragment length polymorphism
SDA	Strand displacement amplification
SERRS	Surface enhanced raman resonance spectroscopy
SNP	Single nucleotide polymorphism
SSCP	Single-strand conformation polymorphism analysis
SSR	Self sustained replication
TGGE	Temperature gradient gel electrophoresis
3' UTR	3' untranslated region

Table 1 - Mutation Detection Techniques**General:** DNA sequencing, Sequencing by hybridisation**Scanning:** PTT*, SSCP, DGGE, TGGE, Cleavase, Heteroduplex analysis, CMC, Enzymatic mismatch cleavage

5 * Note: not useful for detection of promoter polymorphisms.

Hybridisation Based

Solid phase hybridisation: Dot blots, MASDA, Reverse dot blots, Oligonucleotide arrays (DNA Chips)

Solution phase hybridisation: Taqman™ - US-5210015 & US-5487972 (Hoffmann-La
10 Roche), Molecular Beacons - Tyagi *et al* (1996), Nature Biotechnology, 14, 303; WO 95/13399 (Public Health Inst., New York)**Extension Based:** ARMST™-allele specific amplification (as described in European patent No. EP-B-332435 and US patent No. 5,595,890), ALEX™ - European Patent No. EP 332435 B1 (Zeneca Limited), COPS - Gibbs *et al* (1989), Nucleic Acids Research, 17, 2347.15 **Incorporation Based:** Mini-sequencing, APEX**Restriction Enzyme Based:** RFLP, Restriction site generating PCR**Ligation Based:** OLA**Other:** Invader assay20 **Table 2 - Signal Generation or Detection Systems****Fluorescence:** FRET, Fluorescence quenching, Fluorescence polarisation - United Kingdom Patent No. 2228998 (Zeneca Limited)**Other:** Chemiluminescence, Electrochemiluminescence, Raman, Radioactivity, Colorimetric, Hybridisation protection assay, Mass spectrometry, SERRS - WO 97/05280 (University of
25 Strathclyde).**Table 3 - Further Amplification Methods**

SSR, NASBA, LCR, SDA, b-DNA

30 Preferred mutation detection techniques include ARMST™-allele specific amplification, ALEX™, COPS, Taqman, Molecular Beacons, RFLP, OLA, restriction site based PCR and FRET techniques.

Particularly preferred methods include ARMSTM-allele specific amplification, OLA and RFLP based methods. ARMSTM-allele specific amplification is an especially preferred method.

ARMSTM-allele specific amplification (described in European patent No. EP-B-332435, 5 US patent No. 5,595,890 and Newton et al. (Nucleic Acids Research, Vol. 17, p.2503; 1989)), relies on the complementarity of the 3' terminal nucleotide of the primer and its template. The 3' terminal nucleotide of the primer being either complementary or non-complementary to the specific mutation, allele or polymorphism to be detected. There is a selective advantage for primer extension from the primer whose 3' terminal nucleotide complements the base 10 mutation, allele or polymorphism. Those primers which have a 3' terminal mismatch with the template sequence severely inhibit or prevent enzymatic primer extension. Polymerase chain reaction or unidirectional primer extension reactions therefore result in product amplification when the 3' terminal nucleotide of the primer complements that of the template, but not, or at least not efficiently, when the 3' terminal nucleotide does not complement that of the 15 template.

By way of example, a suitable allele specific primer (ARMS primer) capable of detecting/diagnosing the 2361 "T" polymorphism in Exon 1 is:
5'-GCAAGTTCCACAACCTTCTTT-3' (SEQ ID No. 2). The 3' terminal nucleotide complementing the "A" polymorphism on the anti-sense template strand facilitates efficient 20 primer extension with the suitable enzyme (preferably one lacking 3'-5' exonuclease activity).

In a further aspect, the diagnostic methods of the invention are used to assess the efficacy of therapeutic compounds in the treatment of NK1R ligand mediated diseases, such as asthma.

The polymorphisms identified in the present invention that occur in intron regions or in the promoter region are not expected to alter the amino acid sequence of the NK1 receptor, 25 but may affect the transcription and/or message stability of the sequences and thus affect the level of the receptors in cells.

Assays, for example reporter-based assays, may be devised to detect whether one or more of the above polymorphisms affect transcription levels and/or message stability.

Individuals who carry particular allelic variants of the NK1R gene may therefore exhibit 30 differences in their ability to regulate protein biosynthesis under different physiological conditions and will display altered abilities to react to different diseases. In addition, differences in protein regulation arising as a result of allelic variation may have a direct effect

on the response of an individual to drug therapy. The diagnostic methods of the invention may be useful both to predict the clinical response to such agents and to determine therapeutic dose.

In a further aspect, the diagnostic methods of the invention, are used to assess the
5 predisposition and/or susceptibility of an individual to diseases mediated by NK1R ligands. The present invention may be used to recognise individuals who are particularly at risk from developing these conditions.

In a further aspect, the diagnostic methods of the invention are used in the development of new drug therapies which selectively target one or more allelic variants of the NK1R gene.
10 Identification of a link between a particular allelic variant and predisposition to disease development or response to drug therapy may have a significant impact on the design of new drugs. Drugs may be designed to regulate the biological activity of variants implicated in the disease process whilst minimising effects on other variants.

In a further diagnostic aspect of the invention the presence or absence of variant
15 nucleotides is detected by reference to the loss or gain of, optionally engineered, sites recognised by restriction enzymes. For example the polymorphism at position 271 and 272 in exon 3 can be detected by digestion with the restriction enzymes RsaI and Cac8I respectively. Engineered sites include those wherein the primer sequences employed to amplify the target sequence participates along with the nucleotide polymorphism to create a restriction site (see
20 for example, Example 2 section 2 on 809 polymorphism in the 3' UTR (SEQ ID No. 6)).

According to another aspect of the present invention there is provided a nucleic acid comprising any one of the following polymorphisms:
the nucleic acid sequence of EMBL ACCESSION NO. X 65177 with T at position 2286 in exon 1 as defined by the position in EMBL ACCESSION NO. X 65177;
25 the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with T at position 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;
the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with a single base deletion at position 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;
the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with a single base deletion at
30 position 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181;
or a complementary strand thereof or a fragment thereof of at least 20 bases comprising at least one of the polymorphisms.

According to another aspect of the present invention there is provided a nucleic acid comprising any one of the following polymorphisms:

the nucleic acid sequence of EMBL ACCESSION NO. X 65177 with T at position 2286 in exon 1 as defined by the position in EMBL ACCESSION NO. X 65177;

- 5 the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with T at position 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;

the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with a single base deletion at position 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;

the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with a single base deletion at

- 10 position 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181;

the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with C at position 461 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181;

the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with A inserted at position 495 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181;

- 15 the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with G at position 600 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181;

the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with T at position 809 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181;

or a complementary strand thereof or a fragment thereof of at least 20 bases comprising at

- 20 least one of the polymorphisms.

According to another aspect of the present invention there is provided a nucleic acid comprising any one of the following polymorphism containing sequences:

the nucleic acid sequence of SEQ ID No. 1 with T at position 2361 in exon 1 as defined by the position in SEQ ID No. 1; the nucleic acid sequence of EMBL ACCESSION NO. X 65179

- 25 with T at position 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X

65179; the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with a single base

deletion at position 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with a single base

deletion at position 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X

- 30 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with C at position

461 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181;

the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with A inserted at position 495 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with G at position 600 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid
5 sequence of EMBL ACCESSION NO. X 65181 with T at position 809 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of SEQ ID No. 1 with G at position 1371 in the promoter element as defined by the position in SEQ ID No. 1; or a complementary strand thereof or a fragment thereof of at least 20 bases comprising at least one of the polymorphisms.

10 Fragments are at least 17 bases, more preferably at least 20 bases, more preferably at least 30 bases.

The invention further provides nucleotide primers which can detect the polymorphisms of the invention.

According to another aspect of the present invention there is provided an allele specific
15 primer capable of detecting a NK1R gene polymorphism of the invention.

An allele specific primer is used, generally together with a constant primer, in an amplification reaction such as a PCR reaction, which provides the discrimination between alleles through selective amplification of one allele at a particular sequence position e.g. as used for ARMSTM assays. The allele specific primer is preferably 17- 50 nucleotides, more
20 preferably about 17-35 nucleotides, more preferably about 17-30 nucleotides.

An allele specific primer preferably corresponds exactly with the allele to be detected but derivatives thereof are also contemplated wherein about 6-8 of the nucleotides at the 3' terminus correspond with the allele to be detected and wherein up to 10, such as up to 8, 6, 4, 2, or 1 of the remaining nucleotides may be varied without significantly affecting the
25 properties of the primer. Often the nucleotide at the -2 and/or -3 position (relative to the 3' terminus) is mismatched in order to optimise differential primer binding and preferential extension from the correct allele discriminatory primer only.

Primers may be manufactured using any convenient method of synthesis. Examples of such methods may be found in standard textbooks, for example "Protocols for
30 Oligonucleotides and Analogues; Synthesis and Properties," Methods in Molecular Biology Series; Volume 20; Ed. Sudhir Agrawal, Humana ISBN: 0-89603-247-7; 1993; 1st Edition. If required the primer(s) may be labelled to facilitate detection.

According to another aspect of the present invention there is provided an allele-specific oligonucleotide probe capable of detecting a NK1R gene polymorphism of the invention.

The allele-specific oligonucleotide probe is preferably 17- 50 nucleotides, more preferably about 17-35 nucleotides, more preferably about 17-30 nucleotides.

5 The design of such probes will be apparent to the molecular biologist of ordinary skill. Such probes are of any convenient length such as up to 50 bases, up to 40 bases, more conveniently up to 30 bases in length, such as for example 8-25 or 8-15 bases in length. In general such probes will comprise base sequences entirely complementary to the corresponding wild type or variant locus in the gene. However, if required one or more
10 mismatches may be introduced, provided that the discriminatory power of the oligonucleotide probe is not unduly affected. The probes of the invention may carry one or more labels to facilitate detection, such as in Molecular Beacons.

According to another aspect of the present invention there is provided a diagnostic kit comprising one or more diagnostic probe(s) of the invention and/or diagnostic primer(s),
15 particularly an allele-specific oligonucleotide primer, of the invention.

The diagnostic kits may comprise appropriate packaging and instructions for use in the methods of the invention. Such kits may further comprise appropriate buffer(s) and polymerase(s) such as thermostable polymerases, for example taq polymerase. Such kits may also comprise companion/constant primers and/or control primers or probes. A
20 companion/constant primer is one that is part of the pair of primers used to perform PCR. Such primer usually complements the template strand precisely.

In another aspect of the invention, the single nucleotide polymorphisms of this invention may be used as genetic markers in linkage studies. This particularly applies to the polymorphism in exon 1 (position 2361 in SEQ ID No. 1) because of its relatively high
25 frequency (see below). Further preferred polymorphisms of high frequency are at positions 461 and 809 in the 3'UTR (see example 2 below). Those polymorphisms that occur relatively infrequently are useful as markers of low frequency haplotypes.

According to another aspect of the present invention there is provided an allelic variant of human NK1R polypeptide having a C-terminal deletion of 26 amino acids.

30 According to another aspect of the present invention there is provided a method of treating a human in need of treatment with a NK1R ligand antagonist drug in which the method comprises:

- i) diagnosis of a single nucleotide polymorphism in NK1R gene in the human, which diagnosis comprises determining the sequence of the nucleic acid at one or more of positions: 2286 in exon 1 as defined by the position in EMBL ACCESSION NO. X 65177; 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 5 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; and determining the status of the human by reference to polymorphism in the NK1R gene; and
- ii) administering an effective amount of a NK1R ligand antagonist.
- 10 According to another aspect of the present invention there is provided a method of treating a human in need of treatment with a NK1R ligand antagonist drug in which the method comprises:
- (i) diagnosis of a single nucleotide polymorphism in the NK1R gene in the human, which diagnosis comprises determining the sequence of nucleic acid at one of more of positions: 15 2286 in exon 1 as defined by the position in EMBL ACCESSION NO. X 65177; 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; 461 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 20 495 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 600 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 809 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; and determining the status of the human by reference to polymorphism in the NK1R gene; and
- 25 (ii) administering an effective amount of a NK1R ligand antagonist.
- According to another aspect of the present invention there is provided a method of treating a human in need of treatment with an NK1R ligand antagonist drug in which the method comprises:
- (i) diagnosis of a single nucleotide polymorphism in the NK1R gene in the human, which 30 diagnosis comprises determining the sequence of nucleic acid at one of more of positions: 2361 in exon 1 as defined by the position SEQ ID No. 1; 1371 in the promoter element as defined by the position in SEQ ID No. 1;

271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;
272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;
245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181;
461 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
5 495 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
600 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
809 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
and determining the status of the human by reference to polymorphism in the NK1R gene;
and

- 10 (ii) administering an effective amount of a NK1R ligand antagonist.

Preferably determination of the status of the human is clinically useful. Examples of clinical usefulness include deciding which antagonist drug or drugs to administer and/or in deciding on the effective amount of the drug or drugs. The NK1R ligand antagonist may optionally also have activity at the NK2R.

- 15 According to another aspect of the present invention there is provided use of an NK1R ligand antagonist drug in preparation of a medicament for treating a NK1R ligand mediated disease in a human diagnosed as having a single nucleotide polymorphism at one or more of positions:

2286 in exon 1 as defined by the position in EMBL ACCESSION NO. X 65177;

- 20 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;
272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;
245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181.

- According to another aspect of the present invention there is provided use of an NK1R ligand antagonist drug in preparation of a medicament for treating a NK1R ligand mediated
25 disease in a human diagnosed as having a single nucleotide polymorphism at one or more of positions:

2286 in exon 1 as defined by the position in EMBL ACCESSION NO. X 65177;

- 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;
272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;
30 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181;
461 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
495 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;

600 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;

809 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181.

According to another aspect of the present invention there is provided use of an NK1R ligand antagonist drug in preparation of a medicament for treating a NK1R ligand mediated
5 disease in a human diagnosed as having a single nucleotide polymorphism at one or more of positions:

2361 in exon 1 as defined by the position in SEQ ID No. 1;

1371 in the promoter element as defined by the position in SEQ ID No. 1;

271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;

10 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;

245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181;

461 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;

495 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;

600 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;

15 809 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181.

According to another aspect of the present invention there is provided a pharmaceutical pack comprising an NK1R antagonist drug and instructions for administration of the drug to humans diagnostically tested for a single nucleotide polymorphism at one or more of positions:

20 2286 in exon 1 as defined by the position in EMBL ACCESSION NO. X 65177;

271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;

272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;

245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181.

According to another aspect of the present invention there is provided a pharmaceutical
25 pack comprising an NK1R antagonist drug and instructions for administration of the drug to humans diagnostically tested for a single nucleotide polymorphism at one or more positions:

2286 in exon 1 as defined by the position in EMBL ACCESSION NO. X 65177;

271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;

272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;

30 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181;

461 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;

495 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;

600 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
809 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181.

According to another aspect of the present invention there is provided a pharmaceutical pack comprising an NK1R antagonist drug and instructions for administration of the drug to humans diagnostically tested for a single nucleotide polymorphism at one or more positions:

2361 in exon 1 as defined by the position in SEQ ID No. 1;
1371 in the promoter element as defined by the position in SEQ ID No. 1;
271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;
272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;
245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181;
461 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
495 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
600 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
809 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181.

Testing for the presence of the polymorphism in exon 5 is especially preferred because, without wishing to be bound by theoretical considerations, of its resulting in a significant amino acid change in NK1R polypeptide (as explained herein).

The nucleic acid sequences of the invention, particularly those relating to and identifying the single nucleotide polymorphisms identified herein represent a valuable information source with which to identify further sequences of similar identity and characterise individuals in terms of, for example, their identity, haplotype and other sub-groupings, such as susceptibility to treatment with particular drugs. These approaches are most easily facilitated by storing the sequence information in a computer readable medium and then using the information in standard macromolecular structure programs or to search sequence databases using state of the art searching tools such as GCG (Genetics Computer Group), BlastX BlastP, BlastN, FASTA (refer to Altschul et al. J. Mol. Biol. 215:403-410, 1990). Thus, the nucleic acid sequences of the invention are particularly useful as components in databases useful for sequence identity, genome mapping, pharmacogenetics and other search analyses. Generally, the sequence information relating to the nucleic acid sequences and polymorphisms of the invention may be reduced to, converted into or stored in a tangible medium, such as a computer disk, preferably in a computer readable form. For example, chromatographic scan data or peak data, photographic scan or peak data, mass spectrographic data, sequence gel (or other) data.

The invention provides a computer readable medium having stored thereon one or more nucleic acid sequences of the invention. For example, a computer readable medium is provided comprising and having stored thereon a member selected from the group consisting of: a nucleic acid comprising the sequence of a nucleic acid of the invention, a nucleic acid
5 consisting of a nucleic acid of the invention, a nucleic acid which comprises part of a nucleic acid of the invention, which part includes at least one of the polymorphisms of the invention, a set of nucleic acid sequences wherein the set includes at least one nucleic acid sequence of the invention, a data set comprising or consisting of a nucleic acid sequence of the invention or a part thereof comprising at least one of the polymorphisms identified herein. The
10 computer readable medium can be any composition of matter used to store information or data, including, for example, floppy disks, tapes, chips, compact disks, digital disks, video disks, punch cards and hard drives.

In a particular embodiment of the invention there is provided a computer readable medium having stored thereon a member selected from the group consisting of: a nucleic acid
15 comprising SEQ ID No. 1; a set of nucleic acids wherein at least one of said sequences comprises SEQ ID No. 1; a data set representing a nucleic acid sequence comprising SEQ ID No. 1; a nucleic acid consisting of SEQ ID No. 1; a set of nucleic acids wherein at least one of said sequences consists of the sequence of SEQ ID No. 1; a nucleic acid comprising any part (i.e. fragment of at least 20 bases) of a sequence selected from the group consisting of: SEQ
20 ID No. 1, EMBL ACCESSION NO. X 65177, EMBL ACCESSION NO. X 65179, EMBL ACCESSION NO. X 65179 or EMBL ACCESSION NO. X 65181, which part includes at least one of the polymorphisms identified herein.

A computer based method is also provided for performing sequence identification, said method comprising the steps of providing a nucleic acid sequence comprising a
25 polymorphism of the invention in a computer readable medium; and comparing said polymorphism containing nucleic acid sequence to at least one other nucleic acid or polypeptide sequence to identify identity (homology), i.e. screen for the presence of a polymorphism. Such a method is particularly useful in pharmacogenetic studies and in genome mapping studies.

30 In a particular embodiment of the invention there is provided a method for performing sequence identification, said method comprising the steps of providing a nucleic acid sequence comprising a sequence selected from the group consisting of:

the nucleic acid sequence of SEQ ID No. 1 with T at position 2361 in exon 1 as defined by the position in SEQ ID No. 1; the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with T at position 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with a single base deletion at position 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with a single base deletion at position 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with C at position 461 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with A inserted at position 495 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with G at position 600 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with T at position 809 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of SEQ ID No. 1 with G at position 1371 in the promoter element as defined by the position in SEQ ID No. 1; or a complementary strand thereof or a fragment thereof of at least 20 bases comprising at least one of the polymorphisms; and comparing said nucleic acid sequence to at least one other nucleic acid or polypeptide sequence to identify identity.

20 In another embodiment of the invention there is provided a method for performing sequence identification, said method comprising the steps of providing one or more of the following polymorphism containing nucleic acid sequences: the nucleic acid sequence of SEQ ID No. 1 with T at position 2361 in exon 1 as defined by the position in SEQ ID No. 1; the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with T at position 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with a single base deletion at position 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with a single base deletion at position 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with C at position 461 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with A inserted at position 495 in the 3'UTR as defined by the

position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with G at position 600 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with T at position 809 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of SEQ ID No. 1 with G at position 1371 in the promoter element as defined by the position in SEQ ID No. 1; or a complementary strand thereof or a fragment thereof of at least 20 bases comprising at least one of the polymorphisms, in a computer readable medium; and comparing said nucleic acid sequence to at least one other nucleic acid or polypeptide sequence to determine identity.

10 The invention will now be illustrated but not limited by reference to the following Examples. All temperatures are in degrees Celsius.

In the Examples below, unless otherwise stated, the following methodology and materials have been applied.

AMPLITAQ™, available from Perkin-Elmer Cetus, is used as the source of thermostable
15 DNA polymerase.

General molecular biology procedures can be followed from any of the methods described in "Molecular Cloning - A Laboratory Manual" Second Edition, Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory, 1989).

Electropherograms were obtained in a standard manner: data was collected by ABI377
20 data collection software and the wave form generated by ABI Prism sequencing analysis (2.1.2).

EXAMPLES

Example 1

25 Identification of Polymorphisms

1. Methods

DNA Preparation

DNA was prepared from frozen blood samples collected in EDTA following protocol I (Molecular Cloning: A Laboratory Manual, p392, Sambrook, Fritsch and Maniatis, 2nd
30 Edition, Cold Spring Harbor Press, 1989) with the following modifications. The thawed blood was diluted in an equal volume of standard saline citrate instead of phosphate buffered saline to remove lysed red blood cells. Samples were extracted with phenol, then

phenol/chloroform and then chloroform rather than with three phenol extractions. The DNA was dissolved in deionised water.

Template Preparation

Templates were prepared by PCR using the oligonucleotide primers and annealing temperatures set out below. The extension temperature was 72° and denaturation temperature 94°. Generally 50 ng of genomic DNA was used in each reaction and subjected to 35 cycles of PCR.

Exon 1 SEQ ID No. 1 2547 bp

10

A).	Fragment	Forward primer	Reverse Primer	Annealing Temp	Time
	2000-2467	2000-2019	2448-2467	58°	60s

B).	Fragment	Forward Primer	Reverse Primer	Annealing Temp	Time
15	1168-1712	1168-1187	1693-1712	58°	60s

Exon 3 Accession Number X65179 373 bp

	Fragment	Forward Primer	Reverse Primer	Annealing Temp	Time
20	14-318	14-33	299-318	58°	60s

Exon 5 Accession Number X65181 3929 bp

	Fragment	Forward Primer	Reverse Primer	Annealing Temp	Time
25	18-417	18-38	398-417	58°	60s

For dye-primer sequencing these primers were modified to include M13 forward and reverse primer sequences (ABI protocol P/N 402114, Applied Biosystems) at the 5' end of the forward and reverse oligonucleotides respectively.

30 **Dye Primer Sequencing**

Dye-primer sequencing using M13 forward and reverse primers was as described in the ABI protocol P/N 402114 for the ABI Prism™ dye primer cycle sequencing core kit with

"AmpliTaq FS"TM DNA polymerase, modified in that the annealing temperature was 45° and DMSO was added to the cycle sequencing mix to a final concentration of 5 %.

The extension reactions for each base were pooled, ethanol/sodium acetate precipitated, washed and resuspended in formamide loading buffer.

- 5 4.25 % Acrylamide gels were run on an automated sequencer (ABI 377, Applied Biosystems).

2. Results

Exon 1 SEQ ID No. 1

10

A). Nucleotide 2361 C/T Phe (111) TTC/TTT

Allele frequency	TTC	47%
	TTT	53%

- 15 To precisely identify the location of the 2361 polymorphism, its relative location within SEQ ID No. 1 is as follows:

TGCAAGTTCCACAACCTTCTTCCCCATCGCCGCTGTCTTCGC (SEQ ID No. 3)

2341	2361	2381
------	------	------

- 20 B). Nucleotide 1371 A/G

Allele frequency (37 individuals)	A	98.6%
	G	1.4 %

- The polymorphism creates an recognition sequence (GGCCC) for the restriction enzyme, Sau 96I (New England Biolabs). A PCR product (position 1168-1712, 544 bp) containing the
 25 wild type sequence (AGCCC) will not be cleaved by Sau 96I (New England Biolabs).
 Digestion of a heterozygote product (A/GGCCC) will generate products of 203 bp, 341 bp and 540 bp. Digestion of a homozygous variant (GGCCC) will generate products of 203 bp and 341 bp.

30

Exon 3 Accession Number X 65179

Flanking intron

5 Nucleotide 271 G/T

Allele frequency	G	98.5%
	T	1.5%

10 Nucleotide 272 ΔA (note "Δ" indicates deletion)

Frequency	ΔA	4.5%
-----------	----	------

To precisely identify the location of the 271 and 272 polymorphisms, their relative locations
 15 within the X65179 wild-type sequence is as follows:

AAGTCTCTGCCAAGCGCAAGGTGAGCAGGGGGACAGGCAGA (SEQ ID No. 4)

241		271		280
-----	--	-----	--	-----

AAGTCTCTGCCAAGCGCAAGGTGAGCAGGGGGACAGGCAGA (SEQ ID No. 5)

241		272		280
-----	--	-----	--	-----

20 The G271T polymorphism creates a RsaI (GTAC) restriction enzyme recognition site. A
 PCR product (304 bp) containing the wild type sequence will not be digested by RasI.
 Digestion of a heterozyote product will give bands of 304bp, 257bp and 47 bp. Digestion of
 a homozygous variant product will generate bands of 257 bp, 47 bp.

The 272 ΔA polymorphism creates a Cac 8I (GCNNGC) restriction enzyme recognition
 25 site. A PCR product (304 bp) containing the wild type sequence will not be digested by Cac
 8I. Digestion of a heterozyote product will give bands of 304bp, 258bp and 46 bp. Digestion
 of a homozygous variant product will generate bands of 258 bp, 46 bp.

Exon 5 Accession Number X 65181Nucleotide 245 Δ C5 Frequency Δ C 1.5%

This results in premature termination and loss of C-terminal 26 amino acids

... 379 380 381 382 379
 10 S L D L S W T stop
 TCC CTG GAC CTG..... \rightarrow ... TCC TGG ACC TGA

Unless otherwise indicated, all the allele frequencies were determined on the basis of analysis of 34 individuals.

15

Example 2**Identification of Polymorphisms****1. Methods**

All PCR conditions and sequencing protocols are as described in Example 1. Allele
 20 frequencies were determined in a panel of 37 individuals.

Template Preparation**3' UTR Accession Number X65181**

Fragment	Forward Primer	Reverse Primer	Annealing Temp	Time
301-750	301-320	731-750	58°	60s
25 696-1144	696-715	1125-1144	58°	60s

2. Results**3' UTR Accession Number: X65181**

Nucleotide 461	G/C	Allele Frequency	G 72%
30			C 28%

This polymorphism can be detected by digestion with restriction enzyme Dde I

GTTAG...	DdeI negativeCTTAG...	Dde I positive
CAATC...	GAATC...	

Nucleotide 495	A insertion	Allele Frequency	1.4%
5 Nucleotide 600	A/G	Allele Frequency	A 92%
			G 8%

This polymorphism can be detected by digestion with restriction enzyme Ban II

....AAGCCC..	Ban II negative	...GAGCCC...	Ban II positive
....TTCGGG..		...CTCGGG..	

10 Nucleotide 809	C/T	Allele Frequency	C 55%
			T 45%

This polymorphism can be detected by engineered restriction site Psp1406I (AACGTT)

Engineered primer 787-808 **GGGTGAACAAAAGAAGGAACGT** (SEQ ID No. 6) co-operating with the polymorphism C/T to create the Psp1406I (AACGTT) site only if the "T"

15 polymorphism is present in the target sequence.

CLAIMS

What is claimed is:

1. A method for diagnosis of one or more single nucleotide polymorphism(s) in NK1R
5 gene in a human, which method comprises determining the sequence of the nucleic acid of the human at one or more positions:
2361 in exon 1 as defined by the position in SEQ ID No. 1;
1371 in the promoter element as defined by the position in SEQ ID No.1;
271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;
10 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;
245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181;
461 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
495 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
600 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
15 809 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
and determining the status of the human by reference to polymorphism in NK1R.
2. A method according to claim 1 in which the single nucleotide polymorphism at
position 2361 in exon 1 is presence of C and/or T, the single nucleotide polymorphism at
20 position 1371 in the promoter element is presence of A and/or G, the single nucleotide polymorphism at position 271 near exon 3 is presence of G and/or T, the single nucleotide polymorphism at position 272 near exon 3 is presence of A and/or a single base deletion at this position, the single nucleotide polymorphism at position 245 in exon 5 is presence of C and/or a single base deletion at this position, the single nucleotide polymorphism at position
25 461 in the 3'UTR is presence of G and/or C, the single nucleotide polymorphism at position 495 in the 3'UTR is the presence of T and/or a single base insertion of A at this position, single nucleotide polymorphism at position 600 in the 3'UTR is presence of A and/or G, the single nucleotide polymorphism at position 809 in the 3'UTR is presence of C and/or T.
- 30 3. A method as claimed in claim 1 or 2, wherein the region containing the potential polymorphism is amplified by polymerase chain reaction prior to determining the sequence.

4. A method as claimed in any of claims 1 - 3, wherein the presence or absence of the polymorphism is detected by reference to the loss or gain of, optionally engineered, sites recognised by restriction enzymes.
- 5 5. A method according to claim 1 or claim 2, in which the sequence is determined by a method selected from ARMS-allele specific amplification, allele specific hybridisation, oligonucleotide ligation assay and restriction fragment length polymorphism (RFLP).
6. A method as claimed in any of the preceding claims for use in assessing the
10 predisposition and/or susceptibility of an individual to diseases mediated by NK1R ligands.
7. A nucleic acid comprising any one of the following polymorphism containing sequences:
the nucleic acid sequence of SEQ ID No. 1 with T at position 2361 in exon 1 as defined by the
15 position in SEQ ID No. 1;
the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with T at position 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;
the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with a single base deletion at position 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;
20 the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with a single base deletion at position 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181;
the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with C at position 461 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181;
the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with A inserted at position
25 495 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181;
the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with G at position 600 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181;
the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with T at position 809 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181;
30 the nucleic acid sequence of SEQ ID No. 1 with G at position 1371 in the promoter element as defined by the position in SEQ ID No. 1;

or a complementary strand thereof or a fragment thereof of at least 20 bases comprising at least one of the polymorphisms.

8. A diagnostic nucleic acid primer capable of detecting a polymorphism in the NK1R gene at one or more of positions: 2361 in exon 1 as defined by the position SEQ ID No. 1; 1371 in the promoter element as defined by the position SEQ ID No. 1; 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; 461 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 495 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 600 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 809 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181, in the NR1R gene.
9. A diagnostic primer as claimed in claim 8 which is an allele specific primer adapted for use in ARMS.
10. An allele-specific oligonucleotide probe capable of detecting a polymorphism in the NK1R gene at one or more of positions: 2361 in exon 1 as defined by the position in SEQ ID No. 1; 1371 in the promoter element as defined by the position in SEQ ID No. 1; 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; 461 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 495 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 600 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181; 809 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181, in the NR1R gene.
11. A diagnostic kit comprising one or more diagnostic primer(s) as defined in claim 8 or 9 and/or one or more allele-specific oligonucleotide probes(s) as defined in claim 10.

12. An allelic variant of human NK1R polypeptide having a C-terminal deletion of 26 amino acids.
13. A method of treating a human in need of treatment with an NK1R ligand antagonist
5 drug in which the method comprises:
- (i) diagnosis of a single nucleotide polymorphism in the NK1R gene in the human, which diagnosis comprises determining the sequence of nucleic acid at one of more of positions:
- 2361 in exon 1 as defined by the position SEQ ID No. 1;
1371 in the promoter element as defined by the position in SEQ ID No. 1;
10 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;
272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;
245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181;
461 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
495 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
15 600 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
809 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
and determining the status of the human by reference to polymorphism in the NK1R gene;
and
(ii) administering an effective amount of a NK1R ligand antagonist.
- 20
14. Use of an NK1R ligand antagonist drug in preparation of a medicament for treating a NK1R ligand mediated disease, particularly asthma, in a human diagnosed as having a single nucleotide polymorphism at one or more of positions:
- 2361 in exon 1 as defined by the position in SEQ ID No. 1;
25 1371 in the promoter element as defined by the position in SEQ ID No. 1;
271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;
272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;
245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181;
461 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
30 495 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
600 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
809 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181.

15. A pharmaceutical pack comprising an NK1R antagonist drug and instructions for administration of the drug to humans diagnostically tested for a single nucleotide polymorphism at one or more positions:
- 2361 in exon 1 as defined by the position in SEQ ID No. 1;
- 5 1371 in the promoter element as defined by the position in SEQ ID No. 1;
- 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;
- 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179;
- 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181;
- 461 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
- 10 495 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
- 600 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181;
- 809 in the 3' UTR as defined by the position in EMBL ACCESSION NO. X65181.
16. A computer readable medium having stored thereon a member selected from the group
- 15 consisting of: a nucleic acid comprising SEQ ID No. 1; a set of nucleic acids wherein at least one of said sequences comprises SEQ ID No. 1; a data set representing a nucleic acid sequence comprising SEQ ID No. 1; a nucleic acid consisting of SEQ ID No. 1; a set of nucleic acids wherein at least one of said sequences consists of the sequence of SEQ ID No. 1; a nucleic acid comprising any part of a sequence selected from the group consisting of: SEQ
- 20 ID No. 1, EMBL ACCESSION NO. X 65177, EMBL ACCESSION NO. X 65179, EMBL ACCESSION NO. X 65179 or EMBL ACCESSION NO. X 65181, which part includes at least one of the polymorphisms identified in claim 1.
17. A method for performing sequence identification, said method comprising the steps of
- 25 providing a nucleic acid sequence comprising a sequence selected from the group consisting of: the nucleic acid sequence of SEQ ID No. 1 with T at position 2361 in exon 1 as defined by the position in SEQ ID No. 1; the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with T at position 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with a single
- 30 base deletion at position 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with a single base deletion at position 245 in exon 5 as defined by the position in EMBL ACCESSION NO.

X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with C at position 461 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with A inserted at position 495 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with G at position 600 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with T at position 809 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of SEQ ID No. 1 with G at position 1371 in the promoter element as defined by the position in SEQ ID No. 1; or a complementary strand thereof or a fragment thereof of at least 20 bases comprising at least one of the polymorphisms; and comparing said nucleic acid sequence to at least one other nucleic acid or polypeptide sequence to identify identity.

18. A method for performing sequence identification, said method comprising the steps of providing one or more of the following polymorphism containing nucleic acid sequences: the nucleic acid sequence of SEQ ID No. 1 with T at position 2361 in exon 1 as defined by the position in SEQ ID No. 1; the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with T at position 271 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; the nucleic acid sequence of EMBL ACCESSION NO. X 65179 with a single base deletion at position 272 near exon 3 as defined by the position in EMBL ACCESSION NO. X 65179; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with a single base deletion at position 245 in exon 5 as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with C at position 461 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with A inserted at position 495 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with G at position 600 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of EMBL ACCESSION NO. X 65181 with T at position 809 in the 3'UTR as defined by the position in EMBL ACCESSION NO. X 65181; the nucleic acid sequence of SEQ ID No. 1 with G at position 1371 in the promoter element as defined by the position in SEQ ID No. 1; or a complementary strand thereof or a fragment thereof of at least 20 bases comprising at

least one of the polymorphisms, in a computer readable medium; and comparing said nucleic acid sequence to at least one other nucleic acid or polypeptide sequence to determine identity.

SEQUENCE LISTING

<110> Zeneca Limited

5 <120> CHEMICAL COMPOUNDS

<130> LDSG/PHM 70365/WO

<140>

10 <141>

<150> 9816192.0

<151> 1998-07-25

15 <160> 6

<170> PatentIn Ver. 2.1

<210> 1

20 <211> 2547

<212> DNA

<213> Homo sapiens

<400> 1

25 ggatccaatt tttgcccggc ataagtgtat agtaaatttc ccagccttaa agcacttccc 60
gagagatgct ttgagcgctc gcggtaccag tgcgtaaaccg ccgctccccg gctggcgcg 120
gtgtgcgccca actccaacct gcgcgcaagt ctgccggtgc gcgctccagt cccacagctc 180
cgagtccccg cagtgaaagg agggggcggt gcaccggggt agatggggcc ctgaggactc 240
ccgggggttca gttttccgcg gaactctgcc tgcagcagtc tggcgggaaac gtgctgcgga 300
30 ctcaccccat cttggcttct ccaaaagggt ttatacggac tggcgagtct ttgccctgcc 360
tcctccaagt gtctggcacc agttctaccg tttgaaatgg tcttggactg ggatacgagg 420
cctcaaagtc agaagacggc agggcaggat ggaggcgggc agagaaggct ggctgacctg 480
tcctccagcc cctatgcaaa cctggaaggg gaacaggagg aaggaccacc gatgccacc 540
cgagcccggc tctggcctgc aggcttggca ggcgcggagg cggaggctgc cagggtccccg 600
35 ggaggcaaac gcagcgccgc agtgattgct ggcggagagc ccagagccgc gcgtctgagc 660
gacaagctgc ctatgagtgt ggctcctgcg ctcaccaaga ttcgcaggga gctcagccct 720
gtccccagtg attgagcaga ggctcatcca gaggggtcag gtggagggtc caaatggagc 780
ttcncctgga atttggggcc aagtcaccag ggtggctgag gaaagtgtcc tcaaagctta 840
gagactgtca cttcccagggt gaatcagcta gccaggtaac tgagctagat attttgtggg 900
40 ggtgtttcct aaacacagcc tcaggaaagt tgttttcggg acacctggac cagggagtcg 960
tcgcctctggt cttctcggtg gctggagcgc ggcccggagc gcggcgctgg cacatcgccc 1020
ccacacatga cgttttccca ttgccacagg caagccgcct ctgcagagct gtctcagggc 1080

-2-

tctgggcttc attccctgga agttgattgt cctccactcc agctgtttcc caaatccttc 1140
 ctctctccca gcacccctcg tgcaacgacg attccagctg cggaccgcat ctgtgtcagt 1200
 tacttccaag ccacctactg cccctctcgc gagtgctgg ggctcccggc tcgcagactc 1260
 ccacggcaag tagcaagcag caaaaggcgt ggtagctgcg gcggtggaat gagacagttg 1320
 5 tcaacagctg gcgcacgtgc cgcctgctgc accgggactg gcgagtacgc agcccaggta 1380
 ctgccccttc ccagtgcgt ctctgcaggg ggtataaaa gcctcgtgcg cagctaactc 1440
 gcgagctgag caacccgaac cgagaggtgc ccgcgaaact gcaggcggcg gcagcggcag 1500
 caaaagagaa ggaaaaatct ccagctggat acgaagctcc agaactcctg ccataggctc 1560
 agaactttta caggtcgcgc tgcaatgggc cccacttcg ctctaagtc ctcacgcagc 1620
 10 acagggtttt gcctttccct gcggaggaag gagaaatagg agttgcaggc agcagcaggt 1680
 gcataaatgc gggggatctc ttgcttccta gaactgtgac cggtggaatt tctttccctt 1740
 ttctcagttta ccgcaagaga gatgctgtct ccagacttct gaactcaaac gtctcctgaa 1800
 gcttgaaagt ggaggaattc agagccaccg cgggcaggcg ggcagtgcac ccagaagcgt 1860
 ttatattctg agcgccagtt cagctttcaa aaagagtgtc gccagaaaa agccttccac 1920
 15 cctcctgtct ggcttttaga ggaccctgag cccagggcgc cagccacagg actctgctgc 1980
 agaggggggt tgtgtacaga tagtagggct ttaccgccta gcttcgaaat ggataacgtc 2040
 ctcccggtag actcagacct ctcccaaac atctccacta acacctcgga acccaatcag 2100
 ttgctgcaac cagcctggca aattgtcctt tgggcagctg cctacacggc cattgtggtg 2160
 acctctgtgg tgggcaacgt ggtagtgatg tggatcatct tagcccacaa aagaatgagg 2220
 20 acagtgcaga actattttct ggtgaacctg gccttcgcgg aggcctccat ggctgcattc 2280
 aatacagtgg tgaacttcac ctatgctgtc cacaacgaat ggtactacgg cctgtttctac 2340
 tgcaagttcc acaacttctt ccccatcgcc gctgtcttcg ccagtatcta ctccatgacg 2400
 gctgtggcct ttgatagggt agattagcct ttgtgaaaag gcgagaaagt gctcatagag 2460
 gaccatggca ttgctgtgag gtttggaaact ggggtggggt tgggtcaagt ggaagattgg 2520
 25 ccaactctgag ggttttttta ctgatca 2547

<210> 2

<211> 20

<212> DNA

30 <213> Homo sapiens

<400> 2

gcaagttcca caacttcttt

20

35 <210> 3

<211> 41

<212> DNA

<213> Homo sapiens

40 <400> 3

tgcaagttcc acaacttctt ccccatcgcc gctgtcttcg c

41

<210> 4

<211> 40

<212> DNA

<213> Homo sapiens

5

<400> 4

aagtctctgc caagcgcaag gtgagcaggg gacaggcaga

40

<210> 5

10 <211> 40

<212> DNA

<213> Homo sapiens

<400> 5

15 aagtctctgc caagcgcaag gtgagcaggg gacaggcaga

40

<210> 6

<211> 22

<212> DNA

20 <213> Homo sapiens

<400> 6

gggtgaacaa aagaaggaac gt

22

25

30

35

40